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Abstract
Background:  Broccoli is a Brassica vegetable that is believed to possess chemopreventive
properties. Selenium also shows promise as an anticancer agent. Thus, selenium enrichment of
broccoli has the potential to enhance the anticancer properties of broccoli sprouts.
Method: Selenium-enriched broccoli sprouts were prepared using a sodium selenite solution.
Their anticancer properties were evaluated in human prostate cancer cell lines and compared with
those of a control broccoli sprout extract.
Results:  Selenium-enriched broccoli sprouts were superior to normal broccoli sprouts in
inhibiting cell proliferation, decreasing prostate-specific antigen secretion, and inducing apoptosis
of prostate cancer cells. Furthermore, selenium-enriched broccoli sprouts but, not normal broccoli
sprouts, induced a downregulation of the survival Akt/mTOR pathway.
Conclusion: Our results suggest that selenium-enriched broccoli sprouts could potentially be
used as an alternative selenium source for prostate cancer prevention and therapy.
Background
Selenium (Se) is essential for humans and has been
reported to play a beneficial role in the prevention of car-
diovascular disease [1-3] and cancer [4-6]. The main Se
source for humans comes from diet; however, the Se con-
centration in foods varies widely and is dependent on the
Se concentration of the soil in which the food was grown.
People living in Se-poor areas have a very low Se intake,
which is often associated with Se-deficiency-related dis-
eases, such as Keshan disease, Kashin-Beck disease and
cancer [5,7-9].
The generation of various Se-enriched foods would be
beneficial to prevent Se deficiency in people [10,11]. Sci-
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entists have reported the benefits of enriching broccoli
with Se for cancer prevention [12-14]. Broccoli is known
to contain sulforaphane, an active anticancer agent
[15,16]. As a member of the Se-accumulator Brassica fam-
ily, broccoli accumulates Se-methylselenocysteine as the
major Se compound when it is germinated in Se-enriched
media [17,18]. Interestingly, Se-methylselenocysteine is
also known to possess cancer-protective properties
[19,20]. Therefore, Se-enriched broccoli accumulates two
active anticancer agents: sulforaphane and Se-methylse-
lenocysteine.
Recently, broccoli sprouts have received considerable
attention, because they contain ten times more sulforap-
hane than broccoli florets [21,22]. Broccoli sprouts have
also been reported to inhibit cancer growth in vitro and in
vivo  [23-25]. Moreover, epidemiological studies have
shown that both cruciferous vegetables [26] and selenium
[4] may reduce the incidence of prostate cancer. Thus, in
the present study, we investigated the antiproliferative
activity of a control broccoli sprout extract (CSp) and a Se-
enriched broccoli sprout extract (SeSp). We also explored
the underlying mechanism of action in the survival and
apoptosis pathways in human prostate cancer cell lines.
Our results suggest that SeSp acts as a promising Se source
for prostate cancer prevention and therapy.
Methods
Reagents and standards
All reagents used for total Se, Se speciation, and sulforap-
hane analysis were of analytical grade and were purchased
from Wako Pure Chemical (Tokyo, Japan) unless stated
otherwise. For the preparation of solutions and sample
treatment, Ultrapure Milli-Q water (Millipore, Tokyo,
Japan) was used. Cyclohexane and 2,3-diaminonaphtha-
lene, used for total Se determination, were purchased
from Dojindo Laboratories (Tokyo, Japan). Se standards,
sodium selenate, selenomethionine, and Se-methylselen-
ocysteine were purchased from Wako Pure Chemical
(Tokyo, Japan); sodium selenite was purchased from
Sigma Chemical (MO, USA) and selenocystine was pur-
chased from Acros Organic (Geel, Belgium). Sulforaphane
standard was purchased from LKT Laboratories (MN,
USA).
Broccoli sprout extract preparation
SeSp was prepared using the method described by Sugi-
hara et al. [27]. Briefly, broccoli sprout seeds (Tohoku Co.,
Ltd., Ibaraki, Japan) were germinated in 10 ppm of a
sodium selenite solution to produce SeSp or in deionized
water to produce CSp. The total germination period was 7
days. The sprouts were then harvested and kept at -80°C
until extraction.
For Se speciation and cell culture treatment, 500 mg of
broccoli sprouts (wet weight) was extracted in 1 ml of
deionized water by sonication (Branson Sonifier 450, CT,
USA) for 1 minute on ice. After centrifugation at 2,500
rpm for 10 minutes, the supernatant was filtered through
a 0.45- μm membrane filter (Toyo Roshi, Tokyo, Japan).
The extract was prepared on the same day as the Se speci-
ation analysis or cell culture treatment.
Determination of total Se concentration
The total Se content of broccoli sprouts was measured by
a method described previously [28] using a Twinkle
LB970 spectrofluorometer (Berthold Technologies, Bad
Wildbad, Germany) at an excitation wavelength of 378
nm and an emission wavelength of 525 nm. The accuracy
of this analysis was monitored by the measurement of
bovine liver SRM 1577b as the reference material
(National Institute of Standards and Technology, MD,
USA).
Se speciation analysis by HPLC/ICP-MS
Se speciation was measured using high-performance liq-
uid chromatography (HPLC) coupled to inductively cou-
pled plasma mass spectrometry (ICP-MS). Fifty
microliters of extract was injected into an Asahipak GS-
320 HQ size exclusion column (Showa Denko, Tokyo,
Japan) and detected by an ICP-MS (Perkin-Elmer Sciex
ELAN 6100, Ontario, Canada) connected to a GemTip™
cross-flow nebulizer with a Scott-type spray chamber. All
ICP-MS operating parameters were adjusted to obtain
maximum signal intensity. The instrumental operating
conditions are given in Additional File 1.
Sulforaphane analysis by HPLC
Sulforaphane extraction and analysis were performed by
slight modification of the method described by Liang et
al. [29]. Briefly, 500 mg of broccoli sprouts (wet weight)
was homogenized by sonication in 1 ml of de-ionized
water for 1 minute on ice. After incubation at room tem-
perature for 30 minutes, the homogenate was extracted
three times with 5 ml of methylene chloride. The methyl-
ene chloride fractions were combined and salted with 1 g
of anhydrous sodium sulfate. The methylene chloride
fraction was then dried at 30°C using a rotary evaporator
(Eyela Rotary Vacuum Evaporator N-N series, Tokyo,
Japan). The residue was dissolved in acetonitrile and
stored at -80°C until analysis.
Analysis of sulforaphane was performed via the standard
addition method. Sulforaphane standards of 10, 20, and
40 μg/ml in acetonitrile were mixed with the sulforaphane
extract at a ratio of 1:1 (v:v). Fifty microliters of this mixed
sample was then applied to an HPLC system (Waters, MA,
USA). Separation was performed by an Inertsil ODS-3 col-
umn 4.6 × 250 mm (GL Sciences, Tokyo, Japan) with 70%BMC Cancer 2009, 9:414 http://www.biomedcentral.com/1471-2407/9/414
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acetonitrile as the mobile phase at a flow rate of 1 ml/min.
Sulforaphane was detected at a UV absorbance of 254 nm.
Cell culture and treatment
Three human prostate cancer cell lines (LNCaP, PC-3 and
DU-145) were purchased from Dainippon Pharmaceuti-
cal (Tokyo, Japan). One non-cancerous cell line (CHEK-1,
an immortalized human esophageal cell line) was pro-
vided by Dr. H. Matsubara. CHEK-1 was established by
transduction of human papillomavirus type 16 E6/E7 into
primary cultures of esophageal keratinocytes [30]. The cell
lines were cultured in RPMI-1640 medium (Sigma, MO,
USA) supplemented with 10% fetal bovine serum and
antibiotics (100 U/ml penicillin and 100 μg/ml strepto-
mycin).
For cell treatments, various concentrations of CSp and
SeSp extracts were added to the cell culture medium, fol-
lowed by the addition of L-Methioninase (Wako, VA,
USA) in order for SeSp to generate methylselenol. After 24
hours, cells were released from the CSp or SeSp treatment,
the medium was replaced, and cells were harvested at the
indicated time.
Drug sensitivity assay
Cell proliferation analysis was performed with cells in the
presence of various concentrations of broccoli sprout
extracts by a colorimetric methyl thiazolyl tetrazolium
(MTT) assay, as described previously [31]. Briefly, cells (2
× 104 in 50 μl/well) were plated in 96-well plates. After the
initial cell seeding, different concentrations of broccoli
sprout extracts were added and incubated for 24 hours.
Ten microliters of WST-8 assay cell-counting solution
(Dojindo Lab., Tokyo, Japan) was added to each well and
incubated at 37°C for 3 hours. After the addition of 100
μl/well of 1 N HCl, the cell proliferation rate was then
determined by measuring the absorbance at a wavelength
of 450 nm with a reference wavelength of 650 nm. The
absorbance was read using a microtiter plate reader (Bec-
ton-Dickinson, NJ, USA). Results were derived from trip-
licate experiments.
Prostate-Specific Antigen (PSA) analysis
At approximately 80% confluence, the cells were treated
with the IC50 of each sprout extract. After 24 hours, the cell
medium was collected, dead cells and debris were
removed by centrifugation, and the clear supernatant frac-
tion was stored at -80°C until analysis of PSA secretion.
PSA values were determined at the Gunma University
Hospital Laboratory by an immunoenzymatic assay using
an ST AIA-PACK PSA II kit (Tosoh Bioscience, Tokyo,
Japan), following the method described by the manufac-
turer. PSA values were normalized to the total protein
concentration of viable cells, as described elsewhere [32],
using a ND-1000 Spectrophotometer (NanoDrop Tech-
nology, DE, USA).
Flow cytometric analysis
Cell sample preparation and propidium iodide staining
were performed as described previously [31]. At around
80% confluency, the cells were treated with the IC50 of
each sprout extract. For cell cycle distribution experi-
ments, living cells were harvested at 0 (untreated), 24, 48,
and 72 hours and analyzed using a FACScan Coulter
EPICS XL Flow Cytometer (Beckman Coulter, CA, USA).
Microscopic examination
Cells were cultured and treated with CSp and SeSp as
described above. Morphological changes were examined
at the time indicated and photographed using a regular
phase-contrast microscope.
Cell extraction and Western blot analysis
Protein concentrations were determined using a BCA Pro-
tein Assay Kit (Pierce, IL, USA). Protein (40 μg) was elec-
trophoresed on 5-20% Tris-Tricine ReadyGel (Bio-Rad,
Tokyo, Japan), and electro-transferred to a hybond-
enhanced chemiluminescence membrane (Amersham,
Buckinghamshire, UK). Apoptosis-related proteins were
analyzed using caspase-3, caspase-8, caspase-9, and PARP
antibodies in 1:1000 dilutions (Cell Signaling Technol-
ogy, MA, USA). Survival-related proteins were analyzed
using antibodies against total Akt, phospho-Akt (p-Akt),
total mTOR, and phospho-mTOR (p-mTOR) at 1:1000
dilutions (Cell Signaling Technology, MA, USA). Protein
bands were detected using an enhanced chemilumines-
cence detection system (Amersham, Buckinghamshire,
UK). β-actin (Sigma) served as the loading control. Scan-
ning densitometry was performed with Adobe Photoshop
(Apple, Inc., CA, USA), and analyzed with Quantity One
(Bio-Rad, Tokyo, Japan).
Statistical analysis
Results of the total Se and sulforaphane concentrations
were compared using paired t-tests. A two-way ANOVA
was also used to analyze the difference of the effect of CSp
and SeSp to PARP, p-Akt and p-mTOR protein expression.
All statistical analyses were performed by R statistical soft-
ware [33].
Results
Total Se determination, Se speciation, and sulforaphane 
concentration analysis
Total Se analysis showed that the 10 ppm sodium selenite
solution used to germinate the broccoli sprout seeds was
able to increase the Se concentration of the sprouts. The
total Se concentration of SeSp was 10.24 μg/g, which was
significantly higher than that of CSp at 0.01 μg/g of Se
(Additional File 2).BMC Cancer 2009, 9:414 http://www.biomedcentral.com/1471-2407/9/414
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A chromatogram of the Se speciation of SeSp is shown in
Figure 1. The retention time of the major Se compound of
the extract was compared with that of an authentic sele-
nium compound, such as selenite, selenate, Se-methylse-
lenocysteine, selenomethionine, or selenocystine. The
retention time of Se in the SeSp extract was matched to the
retention time of the selenate, selenite, and Se-methylse-
lenocysteine standards at 12.2, 12.9, and 15.7 minutes,
respectively (Figure 1). By contrast, there was no Se peak
detected in the CSp extract (data not shown).
The concentration of selenate, selenite, and Se-methylse-
lenocysteine was then calculated by measuring the large
area below each corresponding peak, which was then
applied to the standard curve made using the standard at
several concentrations. The concentrations of selenate,
selenite, and Se-methylselenocysteine in the SeSp extract
were 2 μM, 6.16 μM, and 24.2 μM, respectively (Addi-
tional File 2).
The sulforaphane analysis showed that the differences in
sulforaphane concentration of CSp (375.87 ± 17.98 μM)
and SeSp (316.53 ± 43.54 μM) were not statistically sig-
nificant (Additional File 2).
Drug sensitivity assay
As shown in Figure 2, treatment with both extracts
resulted in the dose-dependent inhibition of prostate can-
cer cell growth when assessed at 24 hours post-treatment.
In LNCaP cells, the IC50 value of the CSp extract was at 19-
times dilution, while that of the SeSp extract was at 32-
times dilution. In PC-3 cells, the IC50 value of the CSp
extract was at 20-times dilution, and that of the SeSp
extract was at 28-times dilution. In DU-145 cells, the IC50
value of the CSp extract was at 15-times dilution, while
that of the SeSp extract was at 30-times dilution.
For the non-cancerous CHEK-1 cell lines, higher concen-
trations of both sprout extracts were required to inhibit
cell growth. The IC50 value of the CSp extract on CHEK-1
cells was at 7-times dilution, while that of the SeSp extract
was at 14-times dilution. Based on these data, it is tempt-
ing to speculate that SeSp might be less harmful to non-
cancerous cells. The concentration of sulforaphane and
Se-methylselenocysteine at the IC50 dilution of CSp and
SeSp extracts on LNCaP, PC-3, DU-145 and CHEK-1 cells
are shown in Additional File 3.
PC-3 cells demonstrated the highest sensitivity to treat-
ment with CSp and LNCaP cells were most sensitive to
treatment with SeSp. On the other hand, DU-145 cells
demonstrated the lowest sensitivity to CSp treatment and
PC-3 cells were least sensitive to SeSp. Based on these
results, we used LNCaP cells treated with the IC50 values of
CSp and SeSp extracts for further experiments.
PSA analysis
The results of the PSA analysis are shown in Figure 3A. The
PSA analysis was only performed with LNCaP cells, since
PC-3 and DU-145 cells are androgen-independent and do
Selenium speciation of the SeSp extract using HPLC/ICP-MS Figure 1
Selenium speciation of the SeSp extract using HPLC/ICP-MS. cps: counts per second.BMC Cancer 2009, 9:414 http://www.biomedcentral.com/1471-2407/9/414
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not produce PSA [34]. LNCaP cells treated with both
sprout extracts for 24 hours showed significantly
decreased PSA secretion. However, after being released
from the treatment, only cells treated with SeSp main-
tained the suppression of PSA secretion, while cells
treated with CSp regained their normal PSA secretion rate.
Flow cytometric analysis
To investigate whether both sprout extracts could induce
cell cycle changes and cell death in prostate cancer cell
lines, flow cytometric analysis of exponentially grown
LNCaP cells treated with each IC50 was performed. As
shown in Figures 3B and 3C, the induction of G2/M phase
arrest upon treatment with both the CSp and SeSp extracts
was noticeable as early as 24 hours after treatment, and
reached a peak at 38.0-50.2%. These results suggest that
the cells were undergoing cell death after prolonged
mitotic blockage. By 48 hours after SeSp treatment, the
number of sub-G1 (hypodiploid) cells was markedly
increased, reaching peak levels at 72 hours (35.1%). By
contrast, LNCaP cells treated with CSp demonstrated
resistance to this phenomenon, since their cell cycle pat-
tern tended to return to normal at 72 hours after treat-
ment (Figure 3B). These results were similar to those of
Effects of 24 h treatment of various CSp and SeSp concentrations to (A) LNCaP, (B) PC-3, (C) DU-145 and (D) CHEK-1 cells  viability Figure 2
Effects of 24 h treatment of various CSp and SeSp concentrations to (A) LNCaP, (B) PC-3, (C) DU-145 and 
(D) CHEK-1 cells viability. CPI: cell proliferation inhibition.
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Effects of 24 h treatment of CSp and SeSp to LNCaP cells Figure 3
Effects of 24 h treatment of CSp and SeSp to LNCaP cells. Cells treated with CSp regained their normal PSA secre-
tion, cell cycle distribution, and proliferation ability after being released from the CSp treatment. (A) PSA secretion in LNCaP 
cells treated with CSp and SeSp extracts. PSA values were normalized against the total protein concentration of viable cells. (B) 
Effects of CSp and (C) SeSp extracts on the LNCaP cell cycle. Cells were harvested at indicated times and analyzed by flow 
cytometry. (D) Representative photomicrographs of LNCaP cells treated with CSp and (E) SeSp extracts at each IC50 concen-
tration at various time points.
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our PSA analysis (Figure 3A). The kinetics of the cell cycle
distribution of cells treated with sprout extracts are shown
in Figures 3B and 3C.
Microscopic examination
When LNCaP prostate cancer cells were treated with CSp
and SeSp extracts at each IC50, clear morphological
changes were observed 24 hours after treatment (Figure
3D and 3E). Morphological changes in LNCaP cells were
clearly observed 24 hours after treatment with both sprout
extracts, and it was obvious that treatment with SeSp
extracts induced cell death more effectively than CSp in
LNCaP cells. This microscopic examination confirmed
our results from the PSA and flow cytometric analyses,
which indicated that after their release from 24 hours of
CSp treatment, LNCaP cells regained their ability to pro-
liferate and also seemed capable of evading apoptosis
(Figure 3D). As anticipated, this phenomenon was not
observed in cells treated with SeSp (Figure 3E).
Western blot analysis of apoptotic-related proteins
Caspase signaling pathways, consisting of a death recep-
tor-dependent extrinsic pathway and a death receptor-
independent intrinsic pathway, were also examined in
LNCaP cells treated with CSp and SeSp extracts at each
IC50. The expression levels of active caspase-8 for the
extrinsic pathway, caspase-9 for the intrinsic pathway, and
caspase-3 were found to increase in LNCaP cells in a time-
dependent manner (Figure 4A). The changes in the
expression levels of poly (ADP-ribose) polymerase
(PARP), described below, suggested that both sprout
extracts induced apoptosis through both the extrinsic and
intrinsic pathways. The expression levels of PARP, one of
the best biomarkers of apoptosis, were analyzed within 24
hours of treatment with both sprout extracts. Result of
two-way ANOVA analysis showed that the increased PARP
expression induced by both extracts was significantly dif-
ferent (p  < 0.001). The N-terminal fragment of PARP,
which is an 89-kDa peptide cleaved from full-length PARP
(116 kDa), was detected as early as 24 hours after SeSp
treatment in LNCaP cells but at 72 hours in LNCaP cells
treated with CSp (Figure 4A). These results suggest that
SeSp induces apoptosis earlier than CSp in LNCaP cells.
Western blot analysis of survival-related protein
As one of the most important survival signaling pathways
in malignancy, the Akt/mTOR pathway has been reported
to play an important role in determining the chemosensi-
tivity of many kinds of cells [35-37]. We evaluated the
expression of these survival signaling proteins in response
to both sprout extracts in LNCaP cells. Figure 4B shows
that SeSp inhibited the activation of Akt in LNCaP cells in
a time-dependent manner, as shown by the reduced
expression of phosphorylated Akt (p-Akt at Ser473). On
the other hand, the expression of p-Akt in LNCap cells
treated with CSp tended to increase within 72 hours. SeSp
treatment also reduced the expression of phosphorylated
mTOR (p-mTOR at Ser2448), which is the downstream
target of Akt (Figure 4B). By contrast, CSp increased the
presence of phosphorylated mTOR in LNCaP cells at 72
hours (Figure 4B). A two-way ANOVA then confirmed the
effect of both extracts to these survival signaling protein
expressions was significantly different (p < 0.001). These
results indicate that the mTOR pathway might play an
important role in maintaining the survival of LNCaP cells
in response to CSp treatment. Previous in vivo studies have
reported that sulforaphane itself as the active compound
of broccoli sprouts was able to inhibit Akt activation of
prostate tumor tissues [16]; however, it required a much
higher dose and longer treatment period than what we
used in the present study. Taken together, our results sug-
gest that, unlike CSp, SeSp downregulates the Akt/mTOR
pathway of prostate cancer LNCaP cells.
Discussion
Our results suggest that in the SeSp extract, Se accumulates
in the form of Se-methylselenocysteine. This result is in
agreement with those of Sugihara and co-workers [27]
who reported that Se-methylselenocysteine was the major
Se compound that accumulated when broccoli sprout
seeds germinated in an inorganic Se solution. Plants pri-
marily take up inorganic Se, which is then metabolized
into several Se analogs of various sulfur metabolites via
the sulfur assimilation pathway [17]. Although Se toxicity
in plants is thought to be caused by the nonspecific bind-
ing of seleno-amino acids to proteins [38], plants are able
to convert the potentially toxic seleno-amino acids into
non-protein derivatives such as Se-methylselenocysteine
[39]. Se-methylselenocysteine is a mono-methylated Se
and is a precursor of methylselenol, a critical metabolite
in Se chemoprevention [5,20]. Se-methylselenocysteine
can directly enter the methylated pool and be converted to
methylselenol by a lyase-catalyzed reaction [5,20,40]. It
has been reported that Se-methylselenocysteine is able to
inhibit the growth of many types of cancer cells [19,41-
43].
Broccoli sprouts have been reported to inhibit skin and
urinary bladder carcinogenesis in vivo [24,25] and also
inhibit the proliferation of human bladder and prostate
cancer cells in vitro [23,44]. The anticancer properties of
broccoli sprouts occur through their primary active micro-
nutrient, sulforaphane [45], by the induction of mito-
chondria-mediated apoptosis [23], induction of cycle
arrest [23,45], inhibition of histone deacetylase (HDAC)
[46], and the induction of phase 2 enzymes, including
glutathione S-transferase (GST) and quinone oxidore-
ductase 1 (NQO1) [47,48]. Moreover, a recent clinical
study from the UK suggested that broccoli sprouts alsoBMC Cancer 2009, 9:414 http://www.biomedcentral.com/1471-2407/9/414
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Western blot analysis of (A) upregulation of the apoptotic-related proteins and (B) downregulation of cell survival-related pro- teins in LNCaP cells treated with CSp or SeSp for 24 h and harvested at the indicated times Figure 4
Western blot analysis of (A) upregulation of the apoptotic-related proteins and (B) downregulation of cell sur-
vival-related proteins in LNCaP cells treated with CSp or SeSp for 24 h and harvested at the indicated times. * 
indicates the cleaved form measured using densitometric analysis. ✮ indicates that the effects induced by CSp and SeSp are sig-
nificantly different (p < 0.001, by two-way ANOVA).
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interact with the glutathione S-transferase mu 1 (GSTM1)
genotype to disrupt oncogenic signaling pathways [49].
In this study, we have shown that broccoli sprout extracts
inhibit the growth of prostate cancer cell lines in a dose-
dependent manner. Furthermore, the addition of Se
enhances the antiproliferative effects of broccoli sprouts.
In all three prostate cancer cell lines tested, SeSp was supe-
rior to CSp in inhibiting cell proliferation (Figure 2) and
the IC50 of SeSp was almost two-fold lower than that of
CSp. Growth inhibition was accompanied by the suppres-
sion of PSA secretion, a well-accepted biomarker for the
diagnosis and prognosis of prostate disease [50], of
androgen-dependent LNCaP cells.
The induction of apoptosis and the inhibition of survival
signaling pathways in cancer cells are the two main goals
in cancer treatment [37]. Here, we provide evidence that
the inhibition of carcinogenesis by SeSp was mediated
through the regulation of multiple signaling pathways.
Our results suggest that broccoli sprouts induce a G2/M-
phase arrest in prostate cancer cell lines that is accompa-
nied by an increase in sub-G1 cells, which represent a cell
death population. Western blot analysis of LNCaP cells
was then performed to confirm apoptotic cell death. Cell
Proposed schematic charts showing various mechanisms by which CSp and SeSp extracts inhibit LNCaP cell proliferation Figure 5
Proposed schematic charts showing various mechanisms by which CSp and SeSp extracts inhibit LNCaP cell 
proliferation. Both extracts induced apoptosis through the extrinsic caspase-8 and intrinsic caspase-9 pathway. However, 
only the SeSp extract inhibited Akt phosphorylation and downstream mTOR phosphorylation, resulting in the inhibition of cell 
proliferation and survival.
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death was found to be initiated extrinsically via the cas-
pase-8 pathway, intrinsically via the mitochondrial cas-
pase-9 pathway, and also by caspase-3 and PARP
activation. In addition, SeSp was found to downregulate
the Akt/mTOR pathway by decreasing p-Akt expression
and the downstream expression of p-mTOR. Downregula-
tion of these survival signaling pathways was found to
enhance the ability of apoptosis-related proteins to initi-
ate the apoptosis machinery [37] and therefore should be
beneficial for the prevention and treatment of malignant
diseases. Interestingly, the downregulation of the Akt/
mTOR pathway was only observed for SeSp treatment, not
for CSp treatment. In fact, after LNCaP cells were released
from CSp treatment, the expression of p-mTOR in treated
cells tended to increase. This result might explain the rea-
son that LNCaP cells escaped apoptosis and regained their
normal proliferation ability after release from CSp treat-
ment.
A growing body of evidence suggests that products derived
from plants are useful in the prevention and treatment of
cancer. Thus, understanding the mechanisms of action of
such products may provide valuable information for their
possible application in cancer prevention and therapy.
The anticancer activity of broccoli sprouts was first intro-
duced by Fahey et al. [51] in 1997, when they reported its
ability to protect rats from chemically-induced mammary
tumor development. In 2001, Finley et al. [52] introduced
the idea of Se enrichment to broccoli sprouts to extend
their protective role against cancer. In the present study,
we showed that SeSp inhibits cancer cell proliferation by
several different mechanisms (Figure 5). Here, we have
proposed that Se enrichment enhances the cancer cell pro-
liferation inhibition and apoptosis induction of CSp.
Moreover, Se also decreases the risk of cancer recurrence
after release from CSp treatment.
Conclusion
Se is a well-known anticancer agent [5], and broccoli
sprouts are commonly consumed vegetables with antican-
cer properties [51,52]. Thus, although further studies
related to their safety will be necessary, Se-enriched broc-
coli sprouts have potential as a chemopreventive
nutraceutical for prostate cancer management. The anti-
cancer properties of SeSp extract are currently being eval-
uated in our laboratory with a series of different cancer
cell lines, as well as through in vivo experiments using an
animal model.
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